CD14 gene promoter polymorphism in different clinical forms of tuberculosis

FEMS Immunology and Medical Microbiology

Volumn 40, Issue 3, 2004, Pages 207-213

  Pacheco, Eugenia ^a   Fonseca, Carolina ^a   Montes, Carlos ^a   Zabaleta, Jovanny ^a,b   García, Luis F ^a   Arias, Mauricio A ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Polymerase chain reaction restriction fragment length polymorphism; Polymorphism; Soluble CD14; Tuberculosis

Indexed keywords

CD14 ANTIGEN; TUBERCULOSTATIC AGENT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EVALUATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REDUCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD14; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS (GENETICS); TUBERCULOSIS; TUBERCULOSIS, MILIARY; TUBERCULOSIS, PLEURAL; TUBERCULOSIS, PULMONARY;

EID: 1642274761     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00369-9     Document Type: Article

References (47)

1. World Health Organization. Global Tuberculosis Control. WHO Report 2002. Geneva, Switzerland.
2. Flynn J.L., Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 19:2001;93-129.
3. Haziot A., Chen S., Ferrero E., Low M.G., Silber R., Goyert S.M. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J. Immunol. 141:1988;547-552.
4. Jack R.S., Grunwald U., Stelter F., Workalemahu G., Schutt C. Both membrane-bound and soluble forms of CD14 bind to gram-negative bacteria. Eur. J. Immunol. 25:1995;1436-1441.
5. Pugin J., Heumann I.D., Tomasz A., Kravchenko V.V., Akamatsu Y., Nishijima M., Glauser M.P., Tobias P.S., Ulevitch R.J. CD14 is a pattern recognition receptor. Immunity. 1:1994;509-516.
6. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 249:1990;1431-1433.
7. Couturier C., Haeffner-Cavaillon N., Caroff M., Kazatchkine M.D. Binding sites for endotoxins (lipopolysaccharides) on human monocytes. J. Immunol. 147:1991;1899-1904.
8. Ulevitch R.J., Tobias P.S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13:1995;437-457.
9. Bazil V., Baudys M., Hilgert I., Stefanova I., Low M.G., Zbrozek J., Horejsi V. Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol. Immunol. 26:1989;657-662.
10. Bazil V., Strominger J.L. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J. Immunol. 147:1991;1567-1574.
11. Pan Z., Zhou L., Hetherington C.J., Zhang D.E. Hepatocytes contribute to soluble CD14 production, and CD14 expression is differentially regulated in hepatocytes and monocytes. J. Biol. Chem. 275:2000;36430-36435.
12. Su G.L., Dorko K., Strom S.C., Nussler A.K., Wang S.C. CD14 expression and production by human hepatocytes. J. Hepatol. 31:1999;435-442.
13. Jersmann H.P., Hii C.S., Hodge G.L., Ferrante A. Synthesis and surface expression of CD14 by human endothelial cells. Infect. Immun. 69:2001;479-485.
14. Grunwald U., Kruger C., Westermann J., Lukowsky A., Ehlers M., Schutt C. An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids. J. Immunol. Methods. 155:1992;225-232.
15. Frey E.A., Miller D.S., Jahr T.G., Sundan A., Bazil V., Espevik T., Finlay B.B., Wright S.D. Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med. 176:1992;1665-1671.
16. Pugin J., Schurer-Maly C.C., Leturcq D., Moriarty A., Ulevitch R.J., Tobias P.S. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. USA. 90:1993;2744-2748.
17. Hailman E., Vasselon T., Kelley M., Busse L.A., Hu M.C., Lichenstein H.S., Detmers P.A., Wright S.D. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J. Immunol. 156:1996;4384-4390.
18. Horneff G., Sack U., Kalden J.R., Emmrich F., Burmester G.R. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin. Exp. Immunol. 91:1993;207-213.
19. Nockher W.A., Wigand R., Schoeppe W., Scherberich J.E. Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin. Exp. Immunol. 96:1994;15-19.
20. Kruger C., Schutt C., Obertacke U., Joka T., Muller F.E., Knoller J., Koller M., Konig W., Schonfeld W. Serum CD14 levels in polytraumatized and severely burned patients. Clin. Exp. Immunol. 85:1991;297-301.
21. Landmann R., Zimmerli W., Sansano S., Link S., Hahn A., Glauser M.P., Calandra T. Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J. Infect. Dis. 171:1995;639-644.
22. Hayashi J., Masaka T., Ishikawa I. Increased levels of soluble CD14 in sera of periodontitis patients. Infect. Immun. 67:1999;417-420.
23. Lien E., Aukrust P., Sundan A., Muller F., Froland S.S., Espevik T. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 92:1998;2084-2092.
24. Juffermans N.P., Verbon A., van Deventer S.J., Buurman W.A., van Deutekom H., Speelman P., van der P.T. Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis. J. Infect. Dis. 178:1998;1839-1842.
25. Lawn S.D., Labeta M.O., Arias M., Acheampong J.W., Griffin G.E. Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment. Clin. Exp. Immunol. 120:2000;483-487.
26. Baldini M., Lohman I.C., Halonen M., Erickson R.P., Holt P.G., Martinez F.D. A Polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am. J. Respir. Cell Mol. Biol. 20:1999;976-983.
27. Pan Z., Hetherington C.J., Zhang D.E. CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor beta signaling in monocyte development. J. Biol. Chem. 274:1999;23242-23248.
28. Unkelbach K., Gardemann A., Kostrzewa M., Philipp M., Tillmanns H., Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler. Thromb. Vasc. Biol. 19:1999;932-938.
29. Zhang D.E., Hetherington C.J., Tan S., Dziennis S.E., Gonzalez D.A., Chen H.M., Tenen D.G. Sp1 is a critical factor for the monocytic specific expression of human CD14. J. Biol. Chem. 269:1994;11425-11434.
30. Hubacek J.A., Rothe G., Pit'ha J., Skodova Z., Stanek V., Poledne R., Schmitz G. C(-260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation. 99:1999;3218-3220.
31. Klein W., Tromm A., Griga T., Fricke H., Folwaczny C., Hocke M., Eitner K., Marx M., Duerig N., Epplen J.T. A polymorphism in the CD14 gene is associated with Crohn disease. Scand. J. Gastroenterol. 37:2002;189-191.
32. Obana N., Takahashi S., Kinouchi Y., Negoro K., Takagi S., Hiwatashi N., Shimosegawa T. Ulcerative colitis is associated with a promoter polymorphism of lipopolysaccharide receptor gene, CD14. Scand. J. Gastroenterol. 37:2002;699-704.
33. Karhukorpi J., Ikaheimo I., Karvonen J., Karttunen R. Promoter region polymorphism of the CD14 gene (C-159T) is not associated with psoriasis vulgaris. Eur. J. Immunogenet. 29:2002;57-60.
34. Brettschneider J., Ecker D., Bitsch A., Bahner D., Bogumil T., Dressel A., Elitok E., Kitze B., Poser S., Weber F., Tumani H. The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. J. Neuroimmunol. 133:2002;193-197.
35. Ito D., Murata M., Tanahashi N., Sato H., Sonoda A., Saito I., Watanabe K., Fukuuchi Y. Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke. 31:2000;2661-2664.
36. LeVan T.D., Bloom J.W., Bailey T.J., Karp C.L., Halonen M., Martinez F.D., Vercelli D. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J. Immunol. 167:2001;5838-5844.
37. Restrepo L.M., Paris S.C., Merizalde G., Sanchez F.O., Mesa G., Garcia L.F. Nitrites, adenosine deaminase and lymphocyte proliferation in tuberculosis pleurisy. Immunol. Infect. Dis. 4:1994;197-201.
38. Segura R.M., Pascual C., Ocana I., Martinez-Vazquez J.M., Ribera E., Ruiz I., Pelegri M.D. Adenosine deaminase in body fluids: a useful diagnostic tool in tuberculosis. Clin. Biochem. 22:1989;141-148.
39. Carvajal-Carmona L.G., Ophoff R., Service S., Hartiala J., Molina J., Leon P., Ospina J., Bedoya G., Freimer N., Ruiz-Linares A. Genetic demography of Antioquia (Colombia) and the Central Valley of Costa Rica. Hum. Genet. 112:2003;534-541.
40. Arias M.A., Rey Nores J.E., Vita N., Stelter F., Borysiewicz L.K., Ferrara P., Labeta M.O. Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J. Immunol. 164:2000;3480-3486.
41. Rey Nores J.E., Bensussan A., Vita N., Stelter F., Arias M.A., Jones M., Lefort S., Borysiewicz L.K., Ferrara P., Labeta M.O. Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur. J. Immunol. 29:1999;265-276.
42. Leung T.F., Tang N.L., Sung Y.M., Li A.M., Wong G.W., Chan I.H., Lam C.W. The C-159T polymorphism in the CD14 promoter is associated with serum total IgE concentration in atopic Chinese children. Pediatr. Allergy Immunol. 14:2003;255-260.
43. Sengler C., Haider A., Sommerfeld C., Lau S., Baldini M., Martinez F., Wahn U., Nickel R. Evaluation of the CD14 C-159 T polymorphism in the German Multicenter Allergy Study cohort. Clin. Exp. Allergy. 33:2003;166-169.
44. Heesen M., Blomeke B., Schluter B., Heussen N., Rossaint R., Kunz D. Lack of association between the -260 C→T promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels. Intensive Care Med. 27:2001;1770-1775.
45. Karhukorpi J., Yan Y., Niemela S., Valtonen J., Koistinen P., Joensuu T., Saikku P., Karttunen R. Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin. Exp. Immunol. 128:2002;326-332.
46. Baldini M., Vercelli D., Martinez F.D. CD14: an example of gene by environment interaction in allergic disease. Allergy. 57:2002;188-192.
47. Yoon H.J., Shin J.H., Yang S.H., Chae D.W., Kim H., Lee D.S., Kim H.L., Kim S., Lee J.S., Kim Y.S. Association of the CD14 gene -159C polymorphism with progression of IgA nephropathy. J. Med. Genet. 40:2003;104-108.